About Axsome Therapeutics (NASDAQ:AXSM)
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The company's product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and Alzheimer's disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for Phase 2 trial of AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXSM
CUSIPN/A
Phone212-332-3241
Debt
Debt-to-Equity Ratio0.40%
Current Ratio2.90%
Quick Ratio2.90%
Price-To-Earnings
Trailing P/E Ratio-2.06
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book3.86
Profitability
EPS (Most Recent Fiscal Year)($1.24)
Net Income$-28,940,000.00
Net MarginsN/A
Return on Equity-132.28%
Return on Assets-73.69%
Miscellaneous
Employees25
Outstanding Shares25,490,000
Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions
What is Axsome Therapeutics' stock symbol?
Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."
How were Axsome Therapeutics' earnings last quarter?
Axsome Therapeutics (NASDAQ:AXSM) released its quarterly earnings results on Wednesday, March, 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.32) by $0.04. View Axsome Therapeutics' Earnings History.
When is Axsome Therapeutics' next earnings date?
What price target have analysts set for AXSM?
4 brokers have issued twelve-month price targets for Axsome Therapeutics' stock. Their predictions range from $13.00 to $31.00. On average, they expect Axsome Therapeutics' share price to reach $19.50 in the next year. View Analyst Ratings for Axsome Therapeutics.
Who are some of Axsome Therapeutics' key competitors?
Some companies that are related to Axsome Therapeutics include BioDelivery Sciences International (BDSI), Checkpoint Therapeutics (CKPT), Adamis Pharmaceuticals (ADMP), Galectin Therapeutics (GALT), Axovant Sciences (AXON), AcelRx Pharmaceuticals (ACRX), Otonomy (OTIC), Bellerophon Therapeutics (BLPH), ContraFect (CFRX), Trevena (TRVN), Merrimack Pharmaceuticals (MACK), OncoMed Pharmaceuticals (OMED), Infinity Pharmaceuticals (INFI), CytoDyn (CYDY), ProQR Therapeutics (PRQR), Leap Therapeutics (LPTX), Cumberland Pharmaceuticals (CPIX) and Conatus Pharmaceuticals (CNAT).
Who are Axsome Therapeutics' key executives?
Axsome Therapeutics' management team includes the folowing people:
- Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 50)
- Ms. Constance Ames, VP of Fin. & Treasurer (Age 32)
- Dr. Randall E. Kaye M.D., Sr. Clinical Advisor (Age 56)
- Mr. John Golubieski, Chief Financial Officer (Age 53)
- Mr. Mark Jacobson M.A., VP of Operations and Sec. (Age 35)
When did Axsome Therapeutics IPO?
(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.
Has Axsome Therapeutics been receiving favorable news coverage?
News coverage about AXSM stock has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Axsome Therapeutics earned a news impact score of 0.19 on Accern's scale. They also gave news headlines about the company an impact score of 46.63 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Axsome Therapeutics?
Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Axsome Therapeutics' stock price today?
One share of AXSM stock can currently be purchased for approximately $2.55.
How big of a company is Axsome Therapeutics?
Axsome Therapeutics has a market capitalization of $66.28 million. The company earns $-28,940,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. Axsome Therapeutics employs 25 workers across the globe.
How can I contact Axsome Therapeutics?
Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.
MarketBeat Community Rating for Axsome Therapeutics (AXSM)
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe AXSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Axsome Therapeutics (NASDAQ:AXSM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Axsome Therapeutics in the last 12 months. Their average twelve-month price target is $19.50, suggesting that the stock has a possible upside of 664.71%. The high price target for AXSM is $31.00 and the low price target for AXSM is $13.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $19.50 | $19.50 | $19.50 | $19.50 |
| Price Target Upside: | 664.71% upside | 245.13% upside | 245.13% upside | 242.11% upside |
Axsome Therapeutics (NASDAQ:AXSM) Consensus Price Target History
Axsome Therapeutics (NASDAQ:AXSM) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Axsome Therapeutics (NASDAQ:AXSM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Axsome Therapeutics (NASDAQ AXSM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 35.20%
Institutional Ownership Percentage: 22.84%
Axsome Therapeutics (NASDAQ AXSM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/23/2015 | Randall Kaye | Insider | Buy | 1,000 | $9.03 | $9,030.00 | |  |
(Data available from 1/1/2013 forward)
Axsome Therapeutics (NASDAQ AXSM) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer
www.reuters.com - April 20 at 10:13 AM |
 | Should You Be Concerned About Axsome Therapeutics Inc’s (NASDAQ:AXSM) Investors?
finance.yahoo.com - April 20 at 10:13 AM |
 | Axsome Therapeutics appoints Nick Pizzie as CFO
seekingalpha.com - April 19 at 4:13 PM |
 | Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer
feeds.benzinga.com - April 19 at 7:34 AM |
 | Axsome Therapeutics (AXSM) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 19 at 3:40 AM |
| Axsome Therapeutics (AXSM) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 4:06 PM |
| Axsome Therapeutics (AXSM) Presents At Needham and Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:01 PM |
| Axsome therapeutics to host R&D day focused on AXS-05 and unmet needs in depression, alzheimer’s disease agitation, and nicotine dependence
seekingalpha.com - March 27 at 10:12 AM |
| Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
finance.yahoo.com - March 27 at 10:12 AM |
| Axsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - March 26 at 10:50 AM |
| Axsome Therapeutics (AXSM) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - March 25 at 8:45 PM |
| Axsome Therapeutics Inc (AXSM) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 25 at 3:30 AM |
| Axsome Therapeutics (AXSM) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - March 13 at 5:48 PM |
 | Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the ... - GlobeNewswire (press release)
globenewswire.com - March 13 at 4:16 PM |
| Head to Head Survey: Axsome Therapeutics (AXSM) versus GW Pharmaceuticals PLC- (GWPH)
www.americanbankingnews.com - March 13 at 3:02 AM |
| Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
finance.yahoo.com - March 12 at 4:01 PM |
| Axsome Therapeutics (AXSM) Releases Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - March 8 at 10:56 AM |
| Axsome Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 7 at 10:53 AM |
| Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 7 at 10:53 AM |
| Axsome Therapeutics Inc (AXSM) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 28 at 3:32 AM |
| Axsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and Dextromethorphan
finance.yahoo.com - February 26 at 10:12 AM |
| Axsome Therapeutics (AXSM) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 26 at 3:20 AM |
| Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - February 15 at 6:01 AM |
| Axsome Therapeutics Inc (AXSM) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 3 at 3:26 AM |
| Axsome Therapeutics Inc (AXSM) Sees Large Increase in Short Interest
www.americanbankingnews.com - January 28 at 1:26 AM |
 | Mid-Day Market Update: Dow Surges Over 100 Points; e.l.f. Beauty Shares Drop
www.nasdaq.com - January 9 at 3:40 PM |
| Mid-Morning Market Update: Markets Mostly Higher; Acuity Brands Profit Misses Views
www.benzinga.com - January 9 at 11:10 AM |
| Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
finance.yahoo.com - January 9 at 11:10 AM |
| Axsome Therapeutics Inc (AXSM) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 5:38 AM |
| Critical Survey: Axsome Therapeutics (AXSM) versus The Competition
www.americanbankingnews.com - January 2 at 11:10 PM |
| Axsome Therapeutics (AXSM) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 1 at 5:20 PM |
| Axsome Therapeutics Target of Unusually Large Options Trading (AXSM)
www.americanbankingnews.com - December 31 at 2:40 AM |
| Axsome Therapeutics (AXSM) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - December 29 at 7:18 PM |
| Analyzing Axsome Therapeutics (AXSM) and Its Peers
www.americanbankingnews.com - December 26 at 5:48 AM |
| Axsome Therapeutics to Present at Biotech Showcase 2018 - GlobeNewswire (press release)
globenewswire.com - December 21 at 11:28 AM |
| Reviewing Axsome Therapeutics (AXSM) and Its Rivals
www.americanbankingnews.com - December 20 at 7:32 AM |
| Axsome Therapeutics to Present at Biotech Showcase 2018
finance.yahoo.com - December 19 at 11:23 AM |
| Axsome Therapeutics Inc (AXSM) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 15 at 3:32 AM |
| Axsome Therapeutics (AXSM) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - December 14 at 4:56 PM |
| Axsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation
finance.yahoo.com - December 14 at 11:34 AM |
| Zacks Investment Research Downgrades Axsome Therapeutics (AXSM) to Hold
www.americanbankingnews.com - December 13 at 4:46 PM |
| Axsome Therapeutics Announces Closing of $9.5 Million Registered Direct Offering - GlobeNewswire (press release)
globenewswire.com - December 6 at 8:46 AM |
 | Axsome Therapeutics (AXSM) Reports 1.78M Share Registered Direct Offering Priced at the Market - StreetInsider.com
www.streetinsider.com - December 3 at 3:40 PM |
| Cantor Fitzgerald Analysts Give Axsome Therapeutics (AXSM) a $13.00 Price Target
www.americanbankingnews.com - December 1 at 6:24 PM |
| Axsome Therapeutics Announces $9.5 Million Registered Direct Offering Priced At-the-Market
finance.yahoo.com - December 1 at 5:58 PM |
| Axsome Therapeutics, Inc. (AXSM) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 20 at 3:58 AM |
| Axsome Therapeutics, Inc. (AXSM) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - November 15 at 5:06 PM |
 | Axsome Therapeutics Reports Third Quarter 2017 Financial Results
www.thestreet.com - November 8 at 6:42 PM |
| Axsome Therapeutics, Inc. (AXSM) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 5:22 AM |
| Axsome Therapeutics (AXSM) and Kite Pharma (KITE) Critical Survey
www.americanbankingnews.com - October 31 at 7:16 PM |
Axsome Therapeutics (NASDAQ:AXSM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Axsome Therapeutics (NASDAQ:AXSM) Income Statement, Balance Sheet and Cash Flow Statement
Axsome Therapeutics (NASDAQ AXSM) Stock Chart for Saturday, April, 21, 2018
Loading chart…
